FIGURE

Figure 8

ID

ZDB-FIG-220816-55

Publication

Herman et al., 2022 - The EGFR/ErbB inhibitor neratinib modifies the neutrophil phosphoproteome and promotes apoptosis and clearance by airway macrophages

Other Figures

All Figure Page

Back to All Figure Page

Figure 8

Neratinib does not alter the numbers or distribution of circulating leukocytes in chronic mouse models of lung disease. Leukocytes in mouse whole-blood samples were analyzed using an automated hematology blood analyzer, which counts total leukocytes as well as differentiates between lymphocytes, neutrophils, and monocytes; the percentages of each leukocyte subset are also analyzed. No differences in the number of leukocytes, or their subsets, were identified between the vehicle- and neratinib-treated groups in the induction dosing (A) or therapeutic dosing (B) model, and similarly, no differences in the percentages of lymphocytes, neutrophils, and monocytes were found between treatment groups in the induction (C) or therapeutic (D) dosing model. Each data point represents data from one mouse; bars show mean ± standard deviation. Unpaired t-tests were used to compare treatment groups within each cell type; p-values were indicated where appropriate.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Front Immunol